{
    "id": 4086,
    "fullName": "MAP2K1 P124Q",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K1 P124Q lies within the protein kinase domain of the Map2k1 protein (UniProt.org). P124Q results in increased Erk1/2 phosphorylation in culture, and is associated with resistance to a Raf inhibitor (PMID: 25370473), but demonstrates autophosphorylation and kinase activity similar to wild-type Map2k1 in another study (PMID: 29753091), and therefore, its effect on Map2k1 protein function is unknown.",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5604,
        "geneSymbol": "MAP2K1",
        "terms": [
            "MAP2K1",
            "CFC3",
            "MAPKK1",
            "MEK1",
            "MKK1",
            "PRKMK1"
        ]
    },
    "variant": "P124Q",
    "createDate": "03/25/2015",
    "updateDate": "03/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 173472,
        "transcript": "NM_002755",
        "gDna": "chr15:g.66436825C>A",
        "cDna": "c.371C>A",
        "protein": "p.P124Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16575,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 P124Q (PMID: 30867592; NCT01953926).",
            "molecularProfile": {
                "id": 3893,
                "profileName": "MAP2K1 P124Q"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60073,
                "name": "lymphatic system cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7602,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7601,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7593,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25915,
                "profileName": "BRAF V600E MAP2K1 P124Q"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3893,
            "profileName": "MAP2K1 P124Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25913,
            "profileName": "BRAF V600K MAP2K1 P124Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25915,
            "profileName": "BRAF V600E MAP2K1 P124Q",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 173472,
            "transcript": "NM_002755",
            "gDna": "chr15:g.66436825C>A",
            "cDna": "c.371C>A",
            "protein": "p.P124Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 173473,
            "transcript": "XM_017022411",
            "gDna": "chr15:g.66436825C>A",
            "cDna": "c.371C>A",
            "protein": "p.P124Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}